News

Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines ...
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage ...
Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage Alzheimer's disease (AD). TML-6 combines ...
Merry Life Launches Global Phase II Trial Of TML-6, The First Drug Targeted At Autolysosome Pathway For Therapy Of Alzheimer's Disease. Date. 2025-06-12 10:45:42. Share on Facebook; ...
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML-6, a novel oral small molecule drug targeting early-stage ...
Allen Baharaff, President and CEO of Galmed Pharmaceuticals commented: "Targeting lipid metabolism with Aramchol, a potent SCD1 inhibitor, is a promising emerging strategy to overcome TKIs, such ...
This process requires autophagosome-lysosome fusion, SNARE complexes, and specific KFERQ-like motifs in PARK7, and is independent of conventional secretion and exosomal pathways. This summary was ...
Oxidative stress induced by 6-OHDA stimulates autophagy flux, which enhances STX17-mediated autolysosome formation, leading to the degradation of autophagosomal contents. However, in response to ...
Delving deeper, the researchers found that blocking autophagosome-lysosome fusion and autolysosomal degradation (the downstream steps of autophagy) abrogated 6-OHDA-induced PARK7 secretion ...
Health Beat: How modern medicine helped mother whose baby had tumor while in the womb; New scientific study proves nicer people live longer; Why many Americans are caregivers in disguise ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 353% surge in interest ...